HALO vs STAA: fair value comparison
Halozyme Therapeutics, Inc. and STAAR Surgical Company · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, STAA currently sits closer to the top of our discount ranking. HALO carries the stronger quality grade.
| HALO | STAA | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $82.27 | $24.34 |
| 12-month range | $63.96–$82.27 | $18.04–$29.55 |
| Sector rank | #14 of 113 Healthcare | #13 of 113 Healthcare |
| Quality grade | A | D |
| Momentum grade | A | — |
| Leverage | High | Low |
| Margin trend | Expanding | — |
| Revenue growth | High | — |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | Fairly Valued | — |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: HALO fair value analysis · STAA fair value analysis